Bayer launches new version of Radimetrics™ at RSNA expanding radiation dose management and contrast analytics capabilities
-- Radimetrics™ Enterprise Platform version 2.5 aggregates data to help radiologists and administrators establish imaging protocols to comply with many current and proposed U.S. Joint Commission Standards for Diagnostic Imaging
-- Advanced contrast analytics provide tools that can help enable sites to improve imaging efficiency and drive quality improvements
-- Expanded data collection and analysis helps establish local dose standards to compare with external benchmarks
WHIPPANY, N.J., Dec. 1, 2014 /PRNewswire/ -- Bayer today unveiled version 2.5 of its Radimetrics™ Enterprise Platform at the 2014 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting. The enhanced version has new features that can help radiologists and hospital administrators meet new 2015 U.S. Joint Commission Diagnostic Imaging Standards, providing information to help optimize radiation dose management and contrast dose analytics to advance image quality and patient care.
"With billions of diagnostic imaging procedures performed every year it's essential that patients aren't exposed to unnecessary levels of radiation," said Christiane Pering, Chief Medical Officer (CMO) and Head of Innovation, Bayer Medical Care. "We recognize the urgency to not only meet the new standards coming into effect next year, but to provide technology that keeps pace with the evolving needs of radiology."
The new software is a next generation upgrade of the platform, which was the first single tool to manage both radiation dose and contrast dose analytics in computed tomography (CT). New features include more advanced contrast dose analytics and new charts and data options to help identify repeat injections and issues associated with intravenous* administration. Enhancements include the ability to align customers' various protocol names to standardized naming conventions from the RadLex® Playbook and further expand capabilities in mammography and general X-ray modalities, improving analytics and workflow efficiencies. Everything can be analyzed in line with external benchmarks, helping administrators further standardize protocols and identify training needs across all enterprise sites.
"The Radimetrics Enterprise Platform allows organizations to collect and analyze data across sites, creating large-scale, real-world dose registries that can help establish benchmarks and scanning parameters," said Dennis Durmis, Head of the Americas Region, Bayer's Radiology business. "We're now seeing how these data may help improve protocols, with registry information being presented at international scientific symposia."
The use of radiation in medicine has led to vast improvements in the diagnosis and treatment of diseases and patient care. Each year, there are more than 3.5 billion X-ray examinations performed worldwide and more than 85 million CT examinations performed in the U.S.1,2 Health authorities and policy makers, such as the U.S. Joint Commission, are increasingly evaluating the risk-benefit profile of patient exposure to ionizing radiation.
About the Radimetrics Enterprise Platform
Bayer's Radimetrics™ Enterprise Platform merges and mobilizes patient dose histories and current exam details across all enterprise sites, bringing analysis and quality solutions to the point of care. This platform provides both radiation dose management and contrast dose analytics management and rapid access to patient dose history. Quality tools at every phase of the workflow let administrators, radiologists, technologists and medical physicists interact with and share personalized dashboards to conduct clinical and operational analyses on-demand.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec. 31, 2013) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.
Follow us on Facebook: www.facebook.com/healthcare.bayer
Follow us on Twitter: https://twitter.com/BayerUS
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments
References
- WHO. Medical Radiation Exposure. Available at http://www.who.int/ionizing_radiation/about/med_exposure/en/. Accessed November, 2014.
- IMV. 2012 CT Market outlook report. Des Plaines, Illinois: IMV Medical Information Division, 2012.
*When used with Medrad® Stellant® CT Injection System with Certegra® Workstation.
PP-REP-US-0028 November 2014
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bayer-launches-new-version-of-radimetrics-at-rsna-expanding-radiation-dose-management-and-contrast-analytics-capabilities-300002471.html
SOURCE Bayer HealthCare
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article